
Rigel Pharmaceuticals, Inc.: updates and filings
Price
$42.53
November 18, 2026Market cap $786M
What Ploutos Investor adds for Rigel Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 10 fiscal years, from 2016
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The reported profit is far larger than a business usually earns on its market value, which usually means one-off or accounting gains. We leave out the P/E and the earnings yield.
- Most of the reported profit is a tax credit, not money earned from customers. We leave out the P/E and the earnings growth, which would not compare with a company that paid tax.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 5, 2026next Feb 4, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
May 2026
March 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 13, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 10, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 5, 2026Results of operationsForm8-K
- Nov 5, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 4, 2026Shares registered for employeesFormS-8
- Aug 4, 2026Results of operationsForm8-K
- Aug 4, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Jul 1, 2026Officer or director changeForm8-K
- Jun 17, 2026Acquisition or disposal of assetsForm8-K
- May 20, 2026Officer or director change, shareholder voteForm8-K
- May 15, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- May 12, 2026Material agreement enteredForm8-K
- May 7, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- May 5, 2026Results of operationsForm8-K
- May 5, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- Apr 21, 2026Material agreement endedForm8-K
- Apr 3, 2026Additional annual meeting materialFormDEFA14A
- Apr 3, 2026Annual meeting proxy statementFormDEF 14A
- Mar 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Mar 3, 2026Results of operationsForm8-K
- Mar 3, 2026Annual reportfor the period to Dec 31, 2025Form10-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 13, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 10, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 5, 2026 | 8-K | Results of operations | Document |
| Nov 5, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 4, 2026 | S-8 | Shares registered for employees | Document |
| Aug 4, 2026 | 8-K | Results of operations | Document |
| Aug 4, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Jul 1, 2026 | 8-K | Officer or director change | Document |
| Jun 17, 2026 | 8-K | Acquisition or disposal of assets | Document |
| May 20, 2026 | 8-K | Officer or director change, shareholder vote | Document |
| May 15, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| May 12, 2026 | 8-K | Material agreement entered | Document |
| May 7, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| May 5, 2026 | 8-K | Results of operations | Document |
| May 5, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| Apr 21, 2026 | 8-K | Material agreement ended | Document |
| Apr 3, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 3, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Mar 3, 2026 | 8-K | Results of operations | Document |
| Mar 3, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC since Feb 4, 2000: every report, 8-K, meeting and letter. Of its other filings (792 in all), the newest.
The full analysis
What do Rigel Pharmaceuticals's filings show?
The filings are where every one of Rigel Pharmaceuticals's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.